ESO Lymphoma Course
Avatar

Should We Add Other Agents Like Obinutuzumab, Lenalidomide, Bortezomib or Ibrutinib to R-CHOP? How to Decide Which DLBCL Patients Should Receive CNS Prophylaxis?

By ESO Lymphoma Course FEATURING Andrew Davies
By ESO Lymphoma Course FEATURING Andrew Davies
46 views
September 3, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Related Content

AUTOPLAY
18:26
William Schaffner

Shingles (Herpes Zoster) Vaccination in Adults: What is the Importan…

21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
13:07
Moffitt Cancer Center

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Feat. J. Chavez
10:04
Tara Graff

How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…

22:09
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2024

New Updates in Frontline DLCBL

Feat. L. Nastoupil
62:02
UChicago Medicine

New Treatment Strategies in DLBCL

Feat. L. Sehn
16:03
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: The New Algorithm for 2L LBCL

Feat. J. Westin
15:26
Moffitt Cancer Center

R/R DLBCL: Are CAR-Ts Superior to Bispecific Antibodies?

Feat. A. Lazaryan
17:21
Daniel Addison

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

15:33
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Has R-CHOP Really Been Replaced as Initial Therapy of DLB…

Feat. J. Friedberg
25:44
Tara Graff

DLBCL Updates From iCML 2023

06:09
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Outcomes of Pts With Richter's Transfo…

Feat. A. Kittai
05:38
GRACE

Epcoritamab in NHL - Incidence and Management of CRS

Feat. T. Phillips
35:28
UNC Lineberger Comprehensive Cancer Center

DLBCL Management: Updates for 2023

Feat. N. Grover
17:11
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Incorporating Novel Agents in Frontline DLBCL

Feat. L. Sehn
16:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

2024 Targeted Therapy Updates for Aggressive B-Cell Lymphomas

Feat. D. Landsburg
26:58
Total Health

Update on Cellular Therapy in Lymphoma

Feat. B. Randolph
17:51
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

Chronic GVHD: A Case-Based Discussion

Feat. L. Perry
15:31
SOHO 2022 Tenth Annual Meeting

SOHO 2022: What's Next in Aggressive B-Cell Lymphoma?

Feat. L. Sehn
35:24
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: Aggressive B-Cell Lymphomas

Feat. G. Nowakowski